» Articles » PMID: 10648273

Association of Low Plasma Cholesterol with Mortality for Cancer at Various Sites in Men: 17-y Follow-up of the Prospective Basel Study

Overview
Journal Am J Clin Nutr
Publisher Elsevier
Date 2000 Jan 29
PMID 10648273
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Low serum cholesterol has been associated with an increased risk of cancer mortality in various studies, which has led to uncertainty regarding the benefit of lower blood cholesterol.

Objective: The aim of our study was to evaluate the association between low blood cholesterol (<5.16 mmol/L) and cancer at sites that have rarely been evaluated. We placed special emphasis on the potential confounding effect of antioxidant vitamins.

Design: Plasma concentrations of cholesterol and antioxidant vitamins were measured in 1971-1973 in 2974 men working in Basel, Switzerland. In 1990, the vital status of all participants was assessed.

Results: Two hundred ninety of the participants had died from cancer, 87 from lung, 30 from prostate, 28 from stomach, and 22 from colon cancer. Group means for plasma cholesterol concentrations did not differ significantly between survivors and those who died from cancer at any of the studied sites. With plasma cholesterol, vitamins C and E, retinol, carotene, smoking, and age accounted for in a Cox model, an increase in total cancer mortality in lung, prostate, and colon but not in stomach cancer mortality was observed in men >60 y of age with low plasma cholesterol. When data from the first 2 y of follow-up were excluded from the analysis, the relative risk estimates remained practically unchanged with regard to lung cancer but decreased for colon, prostate, and overall cancer.

Conclusions: Increased cancer mortality risks associated with low plasma cholesterol were not explained by the confounding effect of antioxidant vitamins, but were attributed in part to the effect of preexisting cancer.

Citing Articles

Association of serum lipids and abnormal lipid score with cancer risk: a population-based prospective study.

Xie Y, Wu Y, Su X, Zhu D, Gao P, Yuan H J Endocrinol Invest. 2023; 47(2):367-376.

PMID: 37458930 DOI: 10.1007/s40618-023-02153-w.


Cholesterol and saturated fatty acids synergistically promote the malignant progression of prostate cancer.

Wang X, Sun B, Wei L, Jian X, Shan K, He Q Neoplasia. 2021; 24(2):86-97.

PMID: 34954451 PMC: 8718564. DOI: 10.1016/j.neo.2021.11.004.


The Role of Metabolic Factors in Renal Cancers.

Rysz J, Franczyk B, Lawinski J, Olszewski R, Gluba-Brzozka A Int J Mol Sci. 2020; 21(19).

PMID: 33008076 PMC: 7582927. DOI: 10.3390/ijms21197246.


KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location.

Tabuso M, Christian M, Kimani P, Gopalakrishnan K, Arasaradnam R Pathol Oncol Res. 2020; 26(4):2537-2548.

PMID: 32594310 PMC: 7471139. DOI: 10.1007/s12253-020-00850-y.


Association between plasma lipid levels during acute coronary syndrome and long-term malignancy risk. The ABC-4* study on heart disease.

Berton G, Cordiano R, Cavuto F, Bagato F, Mahmoud H, Pasquinucci M BMC Cardiovasc Disord. 2019; 19(1):119.

PMID: 31109285 PMC: 6528357. DOI: 10.1186/s12872-019-1092-5.